Quantcast

Latest Ranolazine Stories

2014-05-20 08:32:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve...

2013-03-12 23:01:16

Pain reduction effects of ranolazine most pronounced in patients with poor glucose control A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Ranolazine is approved by the U.S. Food and Drug Administration for the treatment of chronic angina, or chest pain, both...

Beta-Blockers Don’t Lower Cardiovascular Risk
2012-10-03 19:12:35

Lee Rannals for redOrbit.com — Your Universe Online According to a study published in the journal JAMA, the use of beta-blockers was not associated with a lower risk of cardiovascular events. Scientists conducted the study to evaluate the association between beta-blocker use and long-term cardiovascular outcomes. The study included data form patients in the REduction of Atherothrombosis for Continued Health (REACH) registry. This registry included 44,708 patients who met the...

2012-03-26 23:31:44

New research finds ongoing treatment with ticagrelor safe and effective in patients with acute coronary syndrome. Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall in patients with acute coronary syndromes (ACS), which are characterized by symptoms related to obstruction in coronary arteries, which supply blood to the...

2011-08-30 11:45:34

Because of improved management at the acute stage, the risk of dying in hospital after a heart attack has decreased by about 50% in the past 10 years. Likewise, the prescription of recommended medications when patients leave hospital, has resulted in improved survival and fewer recurrent heart attacks. One of the challenges is now to try and further decrease long-term mortality in patients who leave the hospital on "optimal" medical therapy (i.e. who are prescribed all the recommended...

2011-08-30 11:36:08

Influence long-term mortality after a heart attack? Although medication which decreases the risk of angina attacks (chest pain caused by blockage of the arteries that supply the heart), are frequently prescribed in patients who have sustained a myocardial infarction, the possible influence of medication on long-term survival is not known, with the exception of beta-blocking agents, which have been shown to decrease mortality in clinical trials performed 30 years ago. Because antianginal...

2011-07-08 14:03:57

Study finds improvement in chest pain and exercise tolerance New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options). The phase II prospective, double-blind, randomized, controlled clinical trial was conducted at 26 centers in the...

2011-04-04 17:05:59

Ranolazine (Ranexa, Gilead) is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3. Patients with refractory angina, who have chronic chest pain but are not candidates for revascularization, have limited therapeutic options and significant limitations in their...

2009-03-12 13:15:00

PALO ALTO, Calif., March 12 /PRNewswire-FirstCall/ -- The Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that after careful consideration of Astellas Pharma Inc.'s $16.00 per share cash offer with its independent financial and legal advisors, it has determined that Astellas' offer undervalues the Company and is not in the best interests of its stockholders. Accordingly, the Board of Directors recommends that stockholders not tender any of their shares into the...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related